---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-26-002460"
form_type: "8-K"
ticker: "VACH"
cik: "0002006815"
company_name: "Voyager Acquisition Corp./Cayman Islands"
filed_at: "2026-03-18T23:59:59+00:00"
generated_at: "2026-05-15T09:58:25.864041+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Voyager Acquisition shareholders approve Veraxa Biotech deal; 99.67% of Class A shares redeemed

## Summary
- Shareholders approved business combination with Veraxa Biotech AG at March 12, 2026 meeting.
- 25,217,315 Class A shares redeemed (~99.67%), leaving ~$885,556 in trust account.
- After closing, combined company to trade on Nasdaq as VRXA.
- Remaining 82,685 Class A shares will convert into Veraxa Biotech Holding AG shares.
- Closing subject to Nasdaq listing approvals and other customary conditions.

## SEC filing metadata
- accession: 0001829126-26-002460
- form_type: 8-K
- ticker: VACH
- cik: 0002006815
- company_name: Voyager Acquisition Corp./Cayman Islands
- filed_at: 2026-03-18T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.07, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2006815/000182912626002460/0001829126-26-002460-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2006815/000182912626002460/voyageracq_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-26-002460
- JSON: https://secwatch.observer/filing/0001829126-26-002460.json
- Plain text: https://secwatch.observer/filing/0001829126-26-002460.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.